This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Jul 15, 2026
•
3 min read
🧬 FDA approves Celcuity's Revtorpyk (gedatolisib) for PI3K pathway hormone receptor-positive, HER2-negative metastatic breast cancer after Ph3 success, Insilico Medicine, Bora Pharmaceuticals partner on AI drug discovery and commercialization, deal worth $2.5B, Kelun-Biotech's (sacituzumab tirumotecan) plus Merck & Co.'s Keytruda meets primary endpoint in Ph3 for PD-L1-negative non-squamous non-small cell lung cancer
Jul 14, 2026
🧬 Biogen's (diranersen) Ph2 results show tau-targeting antisense oligonucleotide slows decline in Alzheimer's disease, AstraZeneca, Dizal Pharmaceutical strike exclusive global lung cancer license deal, $600M upfront, up to $1.5B total, Biogen, Eisai win FDA approval for subcutaneous Leqembi (lecanemab) initiation therapy in Alzheimer's disease
Jul 13, 2026
🧬 FDA expands Pfizer and Astellas' Padcev (enfortumab vedotin-ejfv) plus Merck & Co.'s Keytruda (pembrolizumab) label to all muscle-invasive bladder cancer patients regardless of cisplatin eligibility, Bayer, Apollo strike €3B ($3.43B) equity deal for minority stake in LARC contraceptives business, CMS, Insilico partner on AI-driven CNS drug discovery, $177M milestones
Jul 10, 2026
🧬 Sanofi's Sarclisa Escena (isatuximab) wins FDA approval as first on-body injector anticancer drug for multiple myeloma, GSK, Hansoh Pharmaceutical's (risvutatug rezetecan) Ph3 trial meets overall survival endpoint in small cell lung cancer, ARPA-H awards up to $160M to teams developing personalized genetic medicines for rare diseases
Jul 9, 2026
🧬 Ipsen's Dysport (abobotulinumtoxinA) meets Ph3 goals in both episodic and chronic migraine trials, Sanofi offers EU concessions to halt probe over misleading flu vaccine campaign against CSL Seqirus, MindRank raises $52M Series B, advancing AI-discovered oral GLP-1 obesity pill to Phase III
Jul 8, 2026
🧬 Vera Therapeutics' Trutakna (atacicept) receives FDA accelerated approval for IgA nephropathy targeting APRIL and BAFF, AstraZeneca, Sino Biopharmaceutical strike ex-China licensing deal for COPD candidate TQC3721, $200M upfront, up to $1.9B total, Evonik invests $100M in Indiana API plant to meet surging U.S. CDMO demand
Jul 7, 2026
🧬 Vertex Pharmaceuticals acquires Crinetics Pharmaceuticals for $10B in largest-ever deal, expanding into endocrine diseases, Kalohexis files confidential IPO, developing melanocortin-based obesity and cancer cachexia treatments, Compass Pathways' COMP360 (psilocybin) demonstrates durable Ph3 response in treatment-resistant depression
Jul 6, 2026
🧬 Novartis to acquire Myricx Bio for up to $1.5B, expanding ADC cancer pipeline with novel NMT inhibitor payloads, Scribe Therapeutics files for IPO, advancing lipid-lowering genetic medicines through clinical trials, Celea Therapeutics raises $180M venture round to advance IPF drug deupirfenidone into late-stage trials
Jul 2, 2026
🧬 Roche's (divarasib) beats Amgen's Lumakras and BMS's Krazati in Ph3 KRAS G12C-mutated non-small cell lung cancer trial, BridgeBio attracts $1B in convertible preferred equity from Sixth Street, HealthCare Royalty for drug launches, AstraZeneca, CSPC Pharmaceutical Group partner on siRNA kidney disease therapies, $30M upfront, $1.77B total
Jul 1, 2026
🧬 FDA approves Orca Bio's Tregzi for graft-versus-host disease prevention in blood cancer patients following Ph3 success, Ipsen to acquire Memo Therapeutics for up to $796M, targeting rare BK virus kidney transplant complication, Anthropic launches Claude Science AI workbench and internal drug discovery program targeting neglected diseases
Jun 30, 2026
🧬 FDA selects Eli Lilly, Regeneron, Fujifilm, Kriya Therapeutics, others for PreCheck Pilot Program to boost U.S. drug manufacturing, BeOne's Brukinsa (zanubrutinib) meets Ph3 goal, reducing progression risk by 43% in first-line mantle cell lymphoma, Boulevard Bio, Metis TechBio strike $1.6B deal for trispecific TCE MTS-128 targeting autoimmune diseases
Jun 29, 2026
🧬 Ipsen to acquire Kartos Therapeutics for up to $1.75B, adding myelofibrosis candidate navtemadlin to oncology pipeline, Viridian Therapeutics' Lumvoa (veligrotug-vvze) wins FDA approval for thyroid eye disease across active and chronic disease, Zymeworks to acquire Theravance for $929M, gaining approved COPD drug Yupelri and lucrative royalty deals
